Arcutis Biotherapeutics (ARQT) to Release Earnings on Wednesday

Arcutis Biotherapeutics (NASDAQ:ARQT) will likely be releasing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Arcutis Biotherapeutics to post earnings of $0.02 per share and revenue of $110.7940 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics Trading Up 2.9%

Shares of Arcutis Biotherapeutics stock opened at $26.61 on Wednesday. The stock has a market capitalization of $3.26 billion, a P/E ratio of -73.92 and a beta of 1.70. Arcutis Biotherapeutics has a 52-week low of $11.75 and a 52-week high of $31.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. The stock’s 50-day simple moving average is $27.52 and its 200 day simple moving average is $23.24.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Mizuho boosted their price target on shares of Arcutis Biotherapeutics from $32.00 to $37.00 and gave the company an “outperform” rating in a research report on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Monday, December 29th. Needham & Company LLC boosted their target price on shares of Arcutis Biotherapeutics from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 26th. Zacks Research lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Arcutis Biotherapeutics in a research report on Wednesday, October 29th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.20.

Insider Transactions at Arcutis Biotherapeutics

In related news, insider Masaru Matsuda sold 40,638 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.28, for a total value of $1,027,328.64. Following the sale, the insider owned 110,003 shares in the company, valued at approximately $2,780,875.84. This trade represents a 26.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Sue-Jean Lin sold 25,272 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $30.78, for a total value of $777,872.16. Following the transaction, the director owned 26,735 shares of the company’s stock, valued at approximately $822,903.30. The trade was a 48.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 216,460 shares of company stock worth $6,063,314. 9.40% of the stock is owned by corporate insiders.

Institutional Trading of Arcutis Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC purchased a new position in shares of Arcutis Biotherapeutics during the fourth quarter worth about $35,000. Truvestments Capital LLC raised its stake in Arcutis Biotherapeutics by 114.2% in the fourth quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock valued at $87,000 after purchasing an additional 1,606 shares in the last quarter. Quantbot Technologies LP bought a new stake in Arcutis Biotherapeutics during the second quarter valued at approximately $145,000. Russell Investments Group Ltd. grew its stake in Arcutis Biotherapeutics by 4,562.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company’s stock worth $157,000 after buying an additional 10,950 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Arcutis Biotherapeutics by 38.4% in the second quarter. BNP Paribas Financial Markets now owns 11,653 shares of the company’s stock valued at $163,000 after acquiring an additional 3,234 shares during the last quarter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.